BR-3006(BR-3006) - 在研适应症：2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病

非在研适应症-

原研机构

Boryung Corp.

在研机构

Boryung Corp.

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 BR-3006 相关的临床试验

NCT06890299

/ Completed临床1期

An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers

The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions

开始日期2024-12-05

申办/合作机构

Boryung Corp.

NCT06890286

/ Completed临床1期

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers

The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting conditions

开始日期2024-12-01

申办/合作机构

Boryung Corp.

NCT05951946

/ Completed临床1期

An Open Label, 6-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers

The purpose of this clinical trial is to evaluate drug-drug interactions and safety between "BR3006-1", "BR3006-2", and "BR3006-3" in healthy volunteers

开始日期2023-07-22

申办/合作机构

Boryung Corp.

100 项与 BR-3006 相关的临床结果

登录后查看更多信息

100 项与 BR-3006 相关的转化医学

登录后查看更多信息

100 项与 BR-3006 相关的专利（医药）

登录后查看更多信息

100 项与 BR-3006 相关的药物交易

登录后查看更多信息